Sylvester Cancer Clinical Trials

TAPUR - Calfa, Carmen

Investigator: Carmen Calfa Email		Coordinator: Carolina Troche +1 (305) 2431481
IRB: 20170529		SDG: Breast Cancer
Disease Site(s): Breast,Colon,Kaposis sarcoma,Kidney,Larynx,Liver,Lymphoid Leukemia,Multiple,Multiple Myeloma,Non-Hodgkin Lymphoma,Pancreas,Prostate,Soft Tissue
Sponsor: ASCO		Enrolling Sites: Aventura Deerfield Gables Kendall Plantation Sylvester

Title: The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"

SGNBCMA-001 - Hoffman, James

Investigator: James Hoffman Email		Coordinator: Alanna Vossen
IRB: 20180619		SDG: Myeloma
Disease Site(s): Multiple Myeloma
Sponsor: SEATTLE GENETICS		Enrolling Sites: Sylvester

Title: SGNBCMA-001: A Phase 1 Study of SEA-BCMA in Patients With Relapsed Or Refractory Multiple Myeloma
Eligibility Criteria - NCT03582033 *This information has been extracted from " www.clinicaltrials.gov"

REGN5458 - Hoffman, James

Investigator: James Hoffman Email		Coordinator: Rafael Perez +1 (786) 4245769
IRB: 20190220		SDG: Myeloma
Disease Site(s): Multiple Myeloma
Sponsor: REGENERON PHARM INC		Enrolling Sites: Sylvester

Title: Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients With Relapsed or Refractory Multiple Myeloma
Eligibility Criteria - NCT03761108 *This information has been extracted from " www.clinicaltrials.gov"

MATCH - Huang, Marilyn

Investigator: Marilyn Huang Email		Coordinator: Carolina Troche +1 (305) 2431481
IRB: 20150671		SDG: Gynecologic Cancer
Disease Site(s): Cervix Uteri,Colon,Corpus Uteri,Kaposis sarcoma,Kidney,Larynx,Liver,Multiple Myeloma,Non-Hodgkin Lymphoma,Other Female Genital,Ovary,Pancreas,Prostate,Soft Tissue
Sponsor: ECOG		Enrolling Sites: Coral Springs Deerfield Gables Hollywood Kendall Plantation Sylvester

Title: Molecular Analysis for Therapy Choice (MATCH)
Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"

20210776 - Kazandjian Dickran

Investigator: Dickran Kazandjian Email		Coordinator: Alanna Vossen
IRB: 20210776		SDG: Myeloma
Disease Site(s): Multiple Myeloma
Sponsor: SANOFI AVENTIS		Enrolling Sites: Deerfield Gables Sylvester

Title: A Phase 3 Randomized, Open Label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple Myeloma
Eligibility Criteria - NCT04270409 *This information has been extracted from " www.clinicaltrials.gov"

20210954 - Kazandjian Dickran

Investigator: Dickran Kazandjian Email		Coordinator:
IRB: 20210954		SDG: Myeloma
Disease Site(s):
Sponsor: MTEM		Enrolling Sites: Sylvester

Title: A Phase 1, Open-Label, Dose-Escalation, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MT-0169 in Patients With Relapsed or Refractory Multiple Myeloma or Non-Hodgkin Lymphoma
Eligibility Criteria - NCT04017130 *This information has been extracted from " www.clinicaltrials.gov"

20201316 - Landgren Carl

Investigator: Carl Landgren Email		Coordinator: Alanna Vossen
IRB: 20201316		SDG: Myeloma
Disease Site(s): Multiple Myeloma
Sponsor: SCCC		Enrolling Sites: Deerfield Gables Sylvester

Title: Phase 2, Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Carfilzomib, Lenalidomide, and Dexamethasone vs Bortezomib, Lenalidomide, and Dexamethasone in Patients with Newly-Diagnosed Multiple Myeloma (ADVANCE)
Eligibility Criteria - NCT04268498 *This information has been extracted from " www.clinicaltrials.gov"

20201536 - Landgren Carl

Investigator: Carl Landgren Email		Coordinator: Olivia Falcon Valdes +1 (305) 2438373
IRB: 20201536		SDG: Myeloma
Disease Site(s): Multiple Myeloma
Sponsor: NCI		Enrolling Sites: Deerfield Sylvester

Title: A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma: Phase 2 Trial of Clinical Applications
Eligibility Criteria - NCT04814615 *This information has been extracted from " www.clinicaltrials.gov"

20210341 - Landgren Carl

Investigator: Carl Landgren Email		Coordinator: Alanna Vossen
IRB: 20210341		SDG: Myeloma
Disease Site(s):
Sponsor: PFIZER		Enrolling Sites: Deerfield Gables Sylvester UMH

Title: MagnetisMM-4 A PHASE 1B/2, OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH OTHER ANTI-CANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA
Eligibility Criteria - NCT05090566 *This information has been extracted from " www.clinicaltrials.gov"

20210675 - Landgren Carl

Investigator: Carl Landgren Email		Coordinator: Alanna Vossen
IRB: 20210675		SDG: Myeloma
Disease Site(s): Multiple Myeloma
Sponsor: Janssen		Enrolling Sites: Deerfield Gables Sylvester

Title: A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone asMaintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who AreMinimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
Eligibility Criteria - NCT03901963 *This information has been extracted from " www.clinicaltrials.gov"

20220203 - Landgren Carl

Investigator: Carl Landgren Email		Coordinator:
IRB: 20220203		SDG: Myeloma
Disease Site(s): Multiple Myeloma
Sponsor: ABBVIE		Enrolling Sites: Sylvester

Title: First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects with Relapsed or Refractory Multiple Myeloma

GO40515 - Lossos, Izidore

Investigator: Izidore Lossos Email		Coordinator:
IRB: 20180638		SDG: Lymphoma
Disease Site(s): Non-Hodgkin Lymphoma
Sponsor: Hoffmann - La Roche		Enrolling Sites: Sylvester

Title: GO40515: A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating The Safety, Tolerability, Pharmacokinetics, And Efficacy OfMosunetuzumab (BTCT4465) In Combination With CHOP or CHP-PolatuzumabVedotin In Patients With B-Cell Non-Hodgkin Lymphoma
Eligibility Criteria - NCT03677141 *This information has been extracted from " www.clinicaltrials.gov"

CPI-006-001 - Merchan, Jaime

Investigator: Jaime Merchan Email		Coordinator: Rakhi Modak +1 (305) 2437387
IRB: 20180279		SDG: Prostate, Bladder, and Kidney Cancers
Disease Site(s): Bladder,Bones and Joints,Cervix Uteri,Colon,Corpus Uteri,Kidney,Lip, Oral Cavity and Pharynx,Lung,Lymphoid Leukemia,Non-Hodgkin Lymphoma,Pancreas,Prostate,Rectum,Soft Tissue
Sponsor: CP		Enrolling Sites: Sylvester

Title: CPI-006-001: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD 73 Antibody, CPI-006, As A Single Agent, In Combination WIith CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers
Eligibility Criteria - NCT03454451 *This information has been extracted from " www.clinicaltrials.gov"

AMC-095 - Ramos, Juan Carlos

Investigator: Juan Carlos Ramos Email		Coordinator:
IRB: 20160656		SDG: Leukemia, Lymphoma, and Myeloma
Disease Site(s): Anus,Lip, Oral Cavity and Pharynx,Lung,Other Hematopoietic
Sponsor: AMC		Enrolling Sites: Sylvester

Title: A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors
Eligibility Criteria - NCT02408861 *This information has been extracted from " www.clinicaltrials.gov"

S17-00978 - Watts, Justin

Investigator: Justin Watts Email		Coordinator: Rafael Perez +1 (786) 4245769
IRB: 20180143		SDG: Leukemia/heme
Disease Site(s): Leukemia, Other
Sponsor: NYULMC		Enrolling Sites: Sylvester

Title: S17-00978:A Phase Ib/IIa Study Evaluating the Safety and Tolerability ofVitamin C in Patients with Intermediate or high Risk Myelodysplastic Syndrome with TET2 Mutations
Eligibility Criteria - NCT03433781 *This information has been extracted from " www.clinicaltrials.gov"

Back to Top